In a dose-escalation portion of LINKER-MM4, linvoseltamab monotherapy demonstrated a high overall response rate (ORR) and minimal residual disease (MRD) negativity in both transplant-eligible and transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM).
The authors wrote that patients with CKD who are younger than 60 years may be at a greater risk of depression.
New IMWG/IMS guidelines enhance risk assessment for multiple myeloma, revealing daratumumab's impact on patient outcomes in real-world settings.
Using the United States Vaccine Adverse Event Reporting System database, investigators found that pneumococcal vaccination led to predominantly nonserious adverse events.
Recent studies reveal that simvastatin does not enhance escitalopram's effects in treating depression, despite improving metabolic health in obese patients.
Pharmacists learn to recognize and combat burnout through self-awareness, open dialogue, and supportive workplace strategies for lasting well-being.
Pharmacists navigate the evolving hematology-oncology landscape, utilizing genetic insights and innovative therapies to enhance patient care.
New research links rapid CAR T-cell expansion to delayed neurotoxicity in patients with multiple myeloma.
Pharmacists enhance food safety by identifying foodborne illness symptoms, especially as FoodNet narrows its focus on E coli and Salmonella.
Claudio Cerchione, MD, PhD, discusses the benefits of anti-CD38 quadruplet regimens for older patients with multiple myeloma.
New intravenous formulation GTx-104 shows promise in improving brain health outcomes for patients with aSAH, offering safer treatment options for pharmacists.
Real-world data from nearly 1.5 million administrations of intranasal esketamine (Spravato) show that its safety profile—including risks of sedation, blood pressure changes, and dissociation—remains consistent with clinical trial findings.
Hercessi shows promising efficacy and safety in treating HER2+ metastatic breast cancer (MBC), with no significant risks from switching from Herceptin.
New research raises questions regarding the efficacy of nirmatrelvir-ritonavir in preventing long COVID, with limited protection found among older adults and high-risk individuals.
Pneumococcal 21-valent conjugate vaccine (PCV21) was found to be immunogenic and safe in individuals living with HIV, providing significant indications of efficacy in immunocompromised patients.
Pharmacists navigate rapid oncology drug therapy changes, enhancing patient care through education, biomarker insights, and tailored counseling strategies.
Pharmacists contribute across direct patient care and education, adherence, and facilitating access.
Expert shares the promising potential of linvoseltamab in treating high-risk smoldering multiple myeloma.
Expert shares the latest advancements in CAR T therapy and novel treatments for myeloma, addressing access challenges and promising new options.
Pharmacists are central to patient education, adherence monitoring, and collaboration within multidisciplinary teams.
Older adults face heightened risks from RSV due to declining immunity and chronic conditions, making vaccination crucial for prevention and health.
Elranatamab enhances MRD negativity in relapsed/refractory multiple myeloma post idecabtagene vicleucel, promising improved treatment outcomes.
Explore the impact of CDK4/6 inhibitors in HR+/HER2– breast cancer treatment and the essential role of oncology pharmacy practice.
The FDA linked cerebral folate deficiency to developmental delays with autistic features, although research remains ongoing.
However, experts say that a causal relationship between acetaminophen and autism has not been established.
New clinical trial results reveal that giredestrant combined with everolimus significantly enhances progression-free survival in patients with advanced ER-positive breast cancer.
Host Craig Beavers discusses the validity of meta-analyses and highlights analyses from European Society of Cardiology (ESC) 2025 with Bill Baker, PharmD, FCCP, FACC, FAHA.
Individualized interventions, medication reconciliation, and postdischarge follow-up help reduce errors and elevate care continuity.
